Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment.
<h4>Background</h4>This study investigated the incidence and predictors of retreatment after discontinuation of either entecavir (ETV) or tenofovir disoproxil fumarate (TDF) treatment in Taiwan.<h4>Methods</h4>A total of 535 non-cirrhotic chronic hepatitis B (CHB) patients un...
Main Authors: | Te-Ling Ma, Tsung-Hui Hu, Chao-Hung Hung, Jing-Houng Wang, Sheng-Nan Lu, Chien-Hung Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0222221 |
Similar Items
-
Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy
by: Hsin-Wei Fang, et al.
Published: (2024-04-01) -
Kinetics in HBsAg after Stopping Entecavir or Tenofovir in Patients with Virological Relapse but Not Clinical Relapse
by: Tzu-Ning Tseng, et al.
Published: (2022-05-01) -
Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy
by: Meng-Ju Lin, et al.
Published: (2023-07-01) -
Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B
by: Te-Sheng Chang, et al.
Published: (2021-01-01) -
Reply to “Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy”
by: Meng-Ju Lin, et al.
Published: (2024-02-01)